Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 8
2005 8
2006 22
2007 31
2008 36
2009 43
2010 55
2011 48
2012 53
2013 55
2014 64
2015 88
2016 65
2017 81
2018 78
2019 88
2020 86
2021 108
2022 110
2023 103
2024 61

Text availability

Article attribute

Article type

Publication date

Search Results

1,161 results

Results by year

Filters applied: . Clear all
Page 1
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R. Rodell CB, et al. Nat Biomed Eng. 2018 Aug;2(8):578-588. doi: 10.1038/s41551-018-0236-8. Epub 2018 May 21. Nat Biomed Eng. 2018. PMID: 31015631 Free PMC article.
Tumour-associated macrophages are abundant in many cancers, and often display an immune-suppressive M2-like phenotype that fosters tumour growth and promotes resistance to therapy. ...Our findings demonstrate the ability of rationally engineered drug-nanoparticle combinati …
Tumour-associated macrophages are abundant in many cancers, and often display an immune-suppressive M2-like phenotype that fosters tu …
Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.
Varshney D, Qiu SY, Graf TP, McHugh KJ. Varshney D, et al. AAPS J. 2021 Jun 28;23(4):90. doi: 10.1208/s12248-021-00620-x. AAPS J. 2021. PMID: 34181117 Review.
When triggered by an agonist, such as imiquimod or resiquimod, the TLR7/8 activation pathway induces cellular and humoral immune responses that can kill cancer cells with high specificity. ...To overcome the key limitations of TLR7/8 agonists as a cancer …
When triggered by an agonist, such as imiquimod or resiquimod, the TLR7/8 activation pathway induces cellular and humoral immune resp …
Modes of action of TLR7 agonists in cancer therapy.
Kobold S, Wiedemann G, Rothenfußer S, Endres S. Kobold S, et al. Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Immunotherapy. 2014. PMID: 25428647 Review.
From the numerous Toll-like receptor agonists, only TLR7 agonists have been approved for cancer treatment, although they are current restricted to topical application. ...Besides NK cells, antigen-specific T cells are the main terminal effectors of TLR7 agoni …
From the numerous Toll-like receptor agonists, only TLR7 agonists have been approved for cancer treatment, although they are c …
Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.
Cai H, Zhang Y, Wang J, Gu J. Cai H, et al. Front Immunol. 2021 Jun 23;12:690869. doi: 10.3389/fimmu.2021.690869. eCollection 2021. Front Immunol. 2021. PMID: 34248982 Free PMC article. Review.
Targeting CSF1/CSF1R for M2 macrophage reprogramming has been widely performed in clinical trials for cancer therapy. Other targets for M2 macrophage reprogramming include Toll-like receptor 7 (TLR7), TLR8, TLR9, CD40, histone deacetylase (HDAC), and PI3Kgamma. ...M …
Targeting CSF1/CSF1R for M2 macrophage reprogramming has been widely performed in clinical trials for cancer therapy. Other targets f …
TLR7 and TLR8 as targets in cancer therapy.
Schön MP, Schön M. Schön MP, et al. Oncogene. 2008 Jan 7;27(2):190-9. doi: 10.1038/sj.onc.1210913. Oncogene. 2008. PMID: 18176600 Review.
Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to their profound antitumoral activity. ...This is achieved independently of TLR7/8 through interference with adenosine receptor signaling p …
Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to thei …
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. Smits EL, et al. Oncologist. 2008 Aug;13(8):859-75. doi: 10.1634/theoncologist.2008-0097. Epub 2008 Aug 13. Oncologist. 2008. PMID: 18701762 Free article. Review.
In view of this, TLR ligands have become interesting targets to use as stand-alone immunotherapeutics or vaccine adjuvants for cancer treatment. TLR7 and TLR8 were found to be closely related, sharing their intracellular endosomal location, as well as their ligands. …
In view of this, TLR ligands have become interesting targets to use as stand-alone immunotherapeutics or vaccine adjuvants for cancer …
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X, Long Y, Chen B, Tong Y, Shan M, Jia X, Hu C, Liu M, Zhou J, Tang F, Lu H, Chen R, Xu P, Huang W, Ren J, Wan Y, Sun J, Li J, Jin G, Gong L. Yu X, et al. J Immunother Cancer. 2022 Oct;10(10):e004590. doi: 10.1136/jitc-2022-004590. J Immunother Cancer. 2022. PMID: 36253000 Free PMC article.
Here, we aimed to improve efficacy for anti-programmed death ligand 1 (PD-L1) therapy by developing a PD-L1/TLR7 dual-targeting nanobody-drug conjugate (NDC), based on the PD-L1 nanobodies and TLR7 agonist we developed. METHODS: PD-L1 nanobodies were obtained by pha …
Here, we aimed to improve efficacy for anti-programmed death ligand 1 (PD-L1) therapy by developing a PD-L1/TLR7 dual-targeting nanob …
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.
Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S. Janku F, et al. Cancer Immunol Res. 2022 Dec 2;10(12):1441-1461. doi: 10.1158/2326-6066.CIR-21-0722. Cancer Immunol Res. 2022. PMID: 36129967 Clinical Trial.
NJH395 is a novel, first-in-class ISAC comprising a Toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 antibody via a noncleavable linker payload. Preclinical characterization showed ISAC-mediated activation of myeloid cells in the presence of antigen-expressin …
NJH395 is a novel, first-in-class ISAC comprising a Toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 antibody via a non …
The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia.
Calore F, Londhe P, Fadda P, Nigita G, Casadei L, Marceca GP, Fassan M, Lovat F, Gasparini P, Rizzotto L, Zanesi N, Jackson D, Mehta S, Nana-Sinkam P, Sampath D, Pollock RE, Guttridge DC, Croce CM. Calore F, et al. Cancer Res. 2018 Dec 1;78(23):6680-6690. doi: 10.1158/0008-5472.CAN-17-3878. Epub 2018 Sep 12. Cancer Res. 2018. PMID: 30209066 Free PMC article.
Here, we evaluate the ability of IMO-8503, a TLR7, 8, and 9 antagonist, to inhibit cancer-induced cachexia. Using EVs isolated from lung and pancreatic cancer cells and from patient plasma samples, we demonstrate that IMO-8503 inhibits cell death induced by c …
Here, we evaluate the ability of IMO-8503, a TLR7, 8, and 9 antagonist, to inhibit cancer-induced cachexia. Using EVs isolated …
Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy.
Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X, Zhou S. Wei B, et al. Nano Lett. 2021 May 26;21(10):4231-4240. doi: 10.1021/acs.nanolett.1c00209. Epub 2021 May 17. Nano Lett. 2021. PMID: 33998789
Herein, tumor-associated macrophage polarization therapy supplemented with PLGA-DOX (PDOX)-induced ICD is developed for cancer treatment. The nanoparticles/bacteria complex (Ec-PR848) is fabricated for tumor targeting and TAM polarization, and PLGA-R848 (PR848) are attache …
Herein, tumor-associated macrophage polarization therapy supplemented with PLGA-DOX (PDOX)-induced ICD is developed for cancer treatm …
1,161 results